MA43347B1 - Compositions et méthodes permettant d'inhiber l'expression du gène de lpa - Google Patents

Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Info

Publication number
MA43347B1
MA43347B1 MA43347A MA43347A MA43347B1 MA 43347 B1 MA43347 B1 MA 43347B1 MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 B1 MA43347 B1 MA 43347B1
Authority
MA
Morocco
Prior art keywords
agents
gene expression
compositions
methods
lpa
Prior art date
Application number
MA43347A
Other languages
English (en)
French (fr)
Other versions
MA43347A (fr
Inventor
Steven Kanner
David Rozema
David Lewis
Lauren Almeida
Darren Wakefield
Vladimir Trubetskoy
Tao Pei
Zhen Li
Aaron Almeida
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA43347A publication Critical patent/MA43347A/fr
Publication of MA43347B1 publication Critical patent/MA43347B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA43347A 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa MA43347B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa

Publications (2)

Publication Number Publication Date
MA43347A MA43347A (fr) 2018-08-08
MA43347B1 true MA43347B1 (fr) 2021-11-30

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43347A MA43347B1 (fr) 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Country Status (37)

Country Link
US (4) US9932586B2 (OSRAM)
EP (2) EP3356529B1 (OSRAM)
JP (4) JP6991966B2 (OSRAM)
KR (2) KR102728481B1 (OSRAM)
CN (1) CN108368506A (OSRAM)
AU (3) AU2016331084B2 (OSRAM)
BR (1) BR112018006489A2 (OSRAM)
CA (1) CA3000397A1 (OSRAM)
CL (1) CL2018000803A1 (OSRAM)
CO (1) CO2018003678A2 (OSRAM)
CR (1) CR20180231A (OSRAM)
CY (1) CY1125263T1 (OSRAM)
DK (1) DK3356529T3 (OSRAM)
EA (1) EA038478B1 (OSRAM)
ES (1) ES2896298T3 (OSRAM)
HR (1) HRP20211410T1 (OSRAM)
HU (1) HUE055942T2 (OSRAM)
IL (3) IL300438A (OSRAM)
JO (2) JOP20210043A1 (OSRAM)
LT (1) LT3356529T (OSRAM)
MA (1) MA43347B1 (OSRAM)
MX (2) MX2018003833A (OSRAM)
MY (1) MY195796A (OSRAM)
PE (1) PE20181139A1 (OSRAM)
PH (1) PH12018500713A1 (OSRAM)
PL (1) PL3356529T3 (OSRAM)
PT (1) PT3356529T (OSRAM)
RS (1) RS62523B1 (OSRAM)
SG (1) SG10202008530TA (OSRAM)
SI (1) SI3356529T1 (OSRAM)
SM (1) SMT202100622T1 (OSRAM)
TN (1) TN2018000094A1 (OSRAM)
TW (3) TWI784934B (OSRAM)
UA (1) UA121998C2 (OSRAM)
UY (1) UY36926A (OSRAM)
WO (1) WO2017059223A2 (OSRAM)
ZA (1) ZA202106265B (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
CN113797348A (zh) * 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
US10294474B2 (en) 2016-09-02 2019-05-21 Arrowhead Pharmaceuticals, Inc. Targeting ligands
IL321221A (en) 2017-04-05 2025-07-01 Silence Therapeutics Gmbh Products and compositions
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
WO2019051402A1 (en) * 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. RNA INTERFERENCE AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
CA3074320A1 (en) * 2017-09-14 2019-03-21 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
AU2018346507B2 (en) 2017-10-04 2025-03-13 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11492624B2 (en) * 2017-10-17 2022-11-08 Arrowheads Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
SI3710586T1 (sl) * 2017-11-13 2023-03-31 Silence Therapeutics Gmbh Nukleinske kisline za inhibiranje izražanja LPA v celici
CA3109553A1 (en) * 2018-09-19 2020-03-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
SI3880818T1 (sl) * 2018-11-13 2023-01-31 Silence Therapeutics Gmbh Nukleinske kisline za inhibiranje izražanja LPA v celici
US11578090B2 (en) * 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US20220307024A1 (en) * 2019-06-17 2022-09-29 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
CN112442499A (zh) * 2019-08-30 2021-03-05 恩智（广州）医药科技有限公司 一种抑制MCM7的siRNA、组合物及其应用
AU2020399636A1 (en) 2019-12-09 2022-06-02 Amgen Inc. RNAi constructs and methods for inhibiting LPA expression
MX2022011801A (es) * 2020-03-23 2022-10-07 Amgen Inc Anticuerpos monoclonales contra acidos nucleicos modificados quimicamente y usos de los mismos.
EP4192954A1 (en) * 2020-08-05 2023-06-14 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting lpa expression
WO2022079221A1 (en) * 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
CA3199678A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
WO2022136466A1 (en) 2020-12-23 2022-06-30 Argonaute RNA Limited Treatment of cardiovascular disease
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
JP2024532271A (ja) 2021-08-30 2024-09-05 ホンジーン バイオテック コーポレイション 官能化ｎ－アセチルガラクトサミンアナログ
EP4402263A2 (en) 2021-09-14 2024-07-24 Argonaute Rna Limited Treatment of cardiovascular disease
EP4403633A1 (en) * 2021-09-18 2024-07-24 Genoval Therapeutics Co., Ltd. Lpa inhibitor and use thereof
US11993626B2 (en) 2021-12-15 2024-05-28 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
TW202340465A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ｌｐａ的ｓｉｒｎａ及綴合物
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024032681A1 (zh) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
KR20250130686A (ko) * 2023-01-13 2025-09-02 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
CN118773191A (zh) * 2023-04-03 2024-10-15 翰森（上海）健康科技有限公司 靶向LPA基因的RNAi剂及其用途
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
WO2024240056A1 (zh) 2023-05-19 2024-11-28 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
WO2024240212A1 (zh) * 2023-05-24 2024-11-28 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
WO2024249680A2 (en) * 2023-05-31 2024-12-05 Arrowhead Pharmaceuticals, Inc. Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof
AU2024280186A1 (en) * 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
US20250215044A1 (en) 2023-09-21 2025-07-03 Ionis Pharmaceuticals, Inc. Compounds and Methods for Inhibiting LPA
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
WO2025087442A1 (zh) * 2023-10-27 2025-05-01 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
WO2025119212A1 (zh) * 2023-12-05 2025-06-12 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
WO2005089287A2 (en) 2004-03-15 2005-09-29 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
RS54578B1 (sr) 2010-02-24 2016-06-30 Arrowhead Research Corporation Preparati za ciljano dopremanje sirnk
US8865675B2 (en) * 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
JP2014504295A (ja) * 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
CA2816041C (en) 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CN104024328A (zh) 2011-08-26 2014-09-03 箭头研究公司 用于体内核酸递送的聚(乙烯基酯)聚合物
AU2012340159B2 (en) * 2011-11-18 2017-09-07 Alnylam Pharmaceuticals, Inc. RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
BR112014004528A2 (pt) 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
KR102657351B1 (ko) 2012-05-24 2024-04-16 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
JP6494533B2 (ja) * 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
BR112015027322A8 (pt) * 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Compostos antissenso conjugados e sua utilização
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Ｈｉｆ２α基因表現之組合物及方法
DK3329002T3 (da) * 2015-07-31 2021-01-11 Alnylam Pharmaceuticals Inc Transthyretin (ttr)-irna-sammensætninger og fremgangsmåder til anvendelse deraf til behandling eller forebyggelse af ttr-forbundne sygdomme
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体

Also Published As

Publication number Publication date
TWI836693B (zh) 2024-03-21
TWI784934B (zh) 2022-12-01
EA201890864A1 (ru) 2018-09-28
KR20180052703A (ko) 2018-05-18
JP2021087459A (ja) 2021-06-10
US10662427B2 (en) 2020-05-26
SI3356529T1 (sl) 2022-01-31
AU2016331084B2 (en) 2022-09-08
EP3356529B1 (en) 2021-08-25
AU2022283623B2 (en) 2025-07-10
JP7442574B2 (ja) 2024-03-04
HUE055942T2 (hu) 2022-01-28
MX2022013010A (es) 2022-11-09
PH12018500713A1 (en) 2018-10-15
PE20181139A1 (es) 2018-07-17
EA038478B1 (ru) 2021-09-03
IL290566B2 (en) 2023-07-01
DK3356529T3 (da) 2021-11-08
TWI880645B (zh) 2025-04-11
IL290566A (en) 2022-04-01
HK1259063A1 (en) 2019-11-22
SMT202100622T1 (it) 2022-01-10
IL290566B1 (en) 2023-03-01
US20200263179A1 (en) 2020-08-20
NZ741086A (en) 2023-11-24
US20170096665A1 (en) 2017-04-06
UY36926A (es) 2017-04-28
JOP20210043A1 (ar) 2017-06-16
US20250115907A1 (en) 2025-04-10
JP2018529732A (ja) 2018-10-11
HRP20211410T1 (hr) 2021-12-24
CY1125263T1 (el) 2023-03-24
US9932586B2 (en) 2018-04-03
TW202449154A (zh) 2024-12-16
ZA202106265B (en) 2023-08-30
JP6991966B2 (ja) 2022-02-03
JOP20160211B1 (ar) 2021-08-17
KR102728481B1 (ko) 2024-11-12
MX2018003833A (es) 2018-06-18
WO2017059223A2 (en) 2017-04-06
PT3356529T (pt) 2021-11-04
CO2018003678A2 (es) 2018-11-30
EP4029941A1 (en) 2022-07-20
WO2017059223A3 (en) 2017-05-11
CN108368506A (zh) 2018-08-03
AU2022283623A1 (en) 2023-02-02
MA43347A (fr) 2018-08-08
SG10202008530TA (en) 2020-10-29
TW201726918A (zh) 2017-08-01
CL2018000803A1 (es) 2018-08-31
BR112018006489A2 (pt) 2018-10-09
EP3356529A4 (en) 2019-09-04
JP2022113835A (ja) 2022-08-04
IL258333A (en) 2018-05-31
JP2024009262A (ja) 2024-01-19
PL3356529T3 (pl) 2021-12-20
RS62523B1 (sr) 2021-11-30
US20180195070A1 (en) 2018-07-12
EP3356529A2 (en) 2018-08-08
AU2016331084A1 (en) 2018-04-19
UA121998C2 (uk) 2020-08-25
KR20240162596A (ko) 2024-11-15
ES2896298T3 (es) 2022-02-24
IL300438A (en) 2023-04-01
WO2017059223A9 (en) 2017-08-17
NZ780687A (en) 2025-06-27
LT3356529T (lt) 2021-12-27
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
IL258333B (en) 2022-03-01
TN2018000094A1 (en) 2019-07-08
TW202332769A (zh) 2023-08-16
CR20180231A (es) 2018-05-31
AU2025242219A1 (en) 2025-10-23
CA3000397A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MA43347B1 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12012501755A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
JOP20190263A1 (ar) عوامل RNAi لتثبيط التعبير عن Alpha- EnaC وطرق استخدامها
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
PH12017502081B1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
AU2017260019A1 (en) Valerian composition and related methods
CR20200117A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)
TR2024009657A1 (tr) Küçük bir aktif koroidal neovaskülerizasyon lezyonunun bulunduğu, yaşa bağlı maküler dejenerasyon tedavisi.